<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01977768</url>
  </required_header>
  <id_info>
    <org_study_id>imm03</org_study_id>
    <secondary_id>imm03</secondary_id>
    <nct_id>NCT01977768</nct_id>
  </id_info>
  <brief_title>TB Immunotherapy Trial With Heat-killed M. Vaccae</brief_title>
  <acronym>imm03</acronym>
  <official_title>Phase III and Dose Ranging Trial of Heat-killed M. Vaccae (V7)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunitor LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Medical University, Ukraine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Immunitor USA Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Stellenbosch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lisichansk Regional Tuberculosis Dispensary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Immunitor LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to carry out multi-country (Ukraine and Mongolia),
      placebo-controlled, randomized Phase III trial in patients with drug-sensitive, multi-drug
      resistant (MDR-TB) and TB-HIV and identify efficacy and safety of whole-cell, heat-killed
      Mycobacterium vaccae formulated as a pill (V7) and consequently conduct confirmatory trials
      in intended registration countries, such as China, Russia and South Africa, etc.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main end-point is negative sputum conversion rate after one month in patients on V7 vs
      placebo arm, both arms will receive conventional anti-tuberculosis chemotherapy consisting of
      1st and/or 2nd line TB drugs according to baseline diagnosis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bacillary sputum smear clearance</measure>
    <time_frame>two years</time_frame>
    <description>blinded assessment of sputum clearance score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in body weight</measure>
    <time_frame>2 years</time_frame>
    <description>comparison of body weight between treatment arm and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in body mass index (BMI)</measure>
    <time_frame>2 years</time_frame>
    <description>comparison of body mass index (BMI) between treatment arm and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in inflammation markers</measure>
    <time_frame>2 years</time_frame>
    <description>changes in erythrocyte sedimentation (ERS) rate and leukocyte counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in liver function test</measure>
    <time_frame>2 years</time_frame>
    <description>changes in ALT, AST and total bilirubin levels</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immune correlates</measure>
    <time_frame>2 years</time_frame>
    <description>Identify changes in immune cells (lymphocytes) resulting from V7 administration</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>V7: Heat-inactivated M. vaccae pill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily pill of V7 together with standard tuberculosis therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one pill of placebo pill once per day together with standard of care TB drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V7</intervention_name>
    <description>One pill of V7 once daily for 30 days together with standard of care TB drugs</description>
    <arm_group_label>V7: Heat-inactivated M. vaccae pill</arm_group_label>
    <other_name>V7 or tableted heat-inactivated mycobacterium vaccae</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmed diagnosis of TB

          -  sputum smear positive

        Exclusion Criteria:

          -  pregnant

          -  likely to be non-compliant due to drug and/or alcohol abuse

          -  mentally unfit to comply with treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aldar Bourinbaiar, PhD, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Immunitor LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Misheel Lung surgery hospital,</name>
      <address>
        <city>Ulaanbaatar</city>
        <state>Ulaanbaatar Region</state>
        <zip>21000</zip>
        <country>Mongolia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lisichansk Regional TB Dispensary</name>
      <address>
        <city>Lisichansk</city>
        <zip>60071</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mongolia</country>
    <country>Ukraine</country>
  </location_countries>
  <reference>
    <citation>Butov DA, Efremenko YV, Prihoda ND, Zaitzeva SI, Yurchenko LV, Sokolenko NI, Butova TS, Stepanenko AL, Kutsyna GA, Jirathitikal V, Bourinbaiar AS. Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7). Immunotherapy. 2013 Oct;5(10):1047-54. doi: 10.2217/imt.13.110.</citation>
    <PMID>24088075</PMID>
  </reference>
  <reference>
    <citation>Efremenko YV, Butov DA, Prihoda ND, Zaitzeva SI, Yurchenko LV, Sokolenko NI, Butova TS, Stepanenko AL, Kutsyna GA, Jirathitikal V, Bourinbaiar AS. Randomized, placebo-controlled phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7). Hum Vaccin Immunother. 2013 Sep;9(9):1852-6. doi: 10.4161/hv.25280. Epub 2013 Jun 19.</citation>
    <PMID>23782489</PMID>
  </reference>
  <reference>
    <citation>Bourinbaiar AS, Mezentseva MV, Butov DA, Nyasulu PS, Efremenko YV, Jirathitikal V, Mishchenko VV, Kutsyna GA. Immune approaches in tuberculosis therapy: a brief overview. Expert Rev Anti Infect Ther. 2012 Mar;10(3):381-9. doi: 10.1586/eri.12.1. Review.</citation>
    <PMID>22397570</PMID>
  </reference>
  <results_reference>
    <citation>Atmakuri K, Penn-Nicholson A, Tanner R, Dockrell HM. Meeting report: 5th Global Forum on TB Vaccines, 20-23 February 2018, New Delhi India. Tuberculosis (Edinb). 2018 Dec;113:55-64. doi: 10.1016/j.tube.2018.08.013. Epub 2018 Aug 24.</citation>
    <PMID>30514514</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 31, 2013</study_first_submitted>
  <study_first_submitted_qc>November 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2013</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>M. vaccae</keyword>
  <keyword>TB</keyword>
  <keyword>MDR-TB</keyword>
  <keyword>V7-immunitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_id>immunotherapy of TB</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.researchgate.net/project/Immunotherapy-of-tuberculosis</doc_url>
      <doc_comment>QUARTERLY UPDATE</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

